Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 4
2012 2
2013 6
2014 3
2015 4
2016 1
2017 2
2018 1
2019 4
2020 1
2021 2
2022 2
2023 4
2024 5
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: krivorotko p. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Rugo HS, et al. Among authors: krivorotko p. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241495 Free PMC article. Clinical Trial.
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group. Oliveira M, et al. Among authors: krivorotko p. Lancet Oncol. 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. Lancet Oncol. 2024. PMID: 39214106 Clinical Trial.
Immunology and immunotherapy in breast cancer.
Semiglazov V, Tseluiko A, Kudaybergenova A, Artemyeva A, Krivorotko P, Donskih R. Semiglazov V, et al. Among authors: krivorotko p. Cancer Biol Med. 2022 Jun 9;19(5):609-18. doi: 10.20892/j.issn.2095-3941.2021.0597. Cancer Biol Med. 2022. PMID: 35676750 Free PMC article. Review.
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.
Jhaveri K, Rugo HS, Cortés J, Oliveira M, Howell SJ, Dalenc F, Gomez HL, Hu X, Krivorotko P, Loibl S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Zhukova L, Nardone A, Wadsworth I, D'Cruz C, Wantenaar T, Das D, de Bruin EC, Turner NC. Jhaveri K, et al. Among authors: krivorotko p. Clin Cancer Res. 2026 May 19. doi: 10.1158/1078-0432.CCR-25-2965. Online ahead of print. Clin Cancer Res. 2026. PMID: 42154572
Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.
Mátrai Z, Kelemen P, Kósa C, Maráz R, Paszt A, Pavlovics G, Sávolt Á, Simonka Z, Tóth D, Kásler M, Kaprin A, Krivorotko P, Vicko F, Pluta P, Kolacinska-Wow A, Murawa D, Jankau J, Ciesla S, Dyttert D, Sabol M, Zhygulin A, Avetisyan A, Bessonov A, Lázár G. Mátrai Z, et al. Among authors: krivorotko p. Pathol Oncol Res. 2022 Jun 15;28:1610377. doi: 10.3389/pore.2022.1610377. eCollection 2022. Pathol Oncol Res. 2022. PMID: 35783360 Free PMC article.
TiLoop Bra Assisted Breast Reconstruction - Our Experience.
Krivorotko PV, Pesotsky RS, Zernov KY, Zhiltsova EK, Tabagua TT, Bessonov AA, Komyahov AV, Nikolaev KS, Rychagov KY, Gigolaeva LP, Zirov KY, Aseeva ZA, Emelyanov AS, Enaldieva DA, Bondarchuk YI, Levchenko VE, Belyaev AM, Semiglazov VF. Krivorotko PV, et al. Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):84-90. Chirurgia (Bucur). 2021. PMID: 33963697 Free article.
[Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer].
Abdullaeva SR, Semiglazova TY, Artemyeva AS, Zagoruiko VA, Kudriashova TI, Filatova LV, Semiglazov VV, Krivorotko PV, Semiglazov VF. Abdullaeva SR, et al. Among authors: krivorotko pv. Arkh Patol. 2024;86(3):5-11. doi: 10.17116/patol2024860315. Arkh Patol. 2024. PMID: 38881000 Russian.
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.
Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, Thill M, Rubio IT, Di Micco R, Bonci EA, Niinikoski L, Kontos M, Karadeniz Cakmak G, Hauptmann M, Peintinger F, Pinto D, Matrai Z, Murawa D, Kadayaprath G, Dostalek L, Nina H, Krivorotko P, Classe JM, Schlichting E, Appelgren M, Paluchowski P, Solbach C, Blohmer JU, Kühn T, The Axsana Study Group. Banys-Paluchowski M, et al. Among authors: krivorotko p. Cancers (Basel). 2021 Mar 29;13(7):1565. doi: 10.3390/cancers13071565. Cancers (Basel). 2021. PMID: 33805367 Free PMC article. Review.
44 results